Skip to main content

Advertisement

Table 4 Pharmacokinetic model-based estimate for cumulative MeHg exposure by diagnostic group

From: Prenatal mercury exposure, autism, and developmental delay, using pharmacokinetic combination of newborn blood concentrations and questionnaire data: a case control study

  Area under the curve (ppb)
  2nd and 3rd trimesters Gestational period
  ASD DD/AtD TD ASD DD/AtD TD
Number 153 32 53 153 32 53
Method 1a       
Median 133 140 140 219 262 203
95th % 428 360 408 693 580 680
Range 0 - 545 0 - 378 0 - 443 0 - 1231 0 - 654 0 - 702
Method 2b       
Median 144 149 152 241 286 218
95th % 438 388 407 732 680 688
Range 0 - 1395 0 - 487 0 - 523 0 - 1703 0 - 713 0 - 800
  1. aMethod 1 converts individual maternal body weight to volume of blood based on weight during each time period
  2. bMethod 2 converts individual maternal body weight to volume of blood based on weight gain during pregnancy